Results 221 to 230 of about 5,972,941 (286)

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab. [PDF]

Pediatr Blood Cancer
Austin B, Pierson SK, Dacus KC, Bustamante MS, Shyamsundar S, Borys L, McHugh K, Irvine A, Jo Y, Bagg A, Lechowicz MJ, Alapat D, Chadburn A, Lim MS, Srkalovic G, van Rhee F, Fajgenbaum DC, Brandstadter JD.   +17 more
europepmc   +1 more source

The Boston All‐in‐One Medial Patellofemoral Complex Reconstruction: A Combined Medial Patellofemoral Ligament and Medial Quadriceps Tendon Femoral Ligament Dynamic Tensioning Technique Using Allograft

Arthroscopy Techniques, EarlyView.
Abstract Recent anatomical understanding of the medial restraints of the patella has evolved over the last decade with a current focus on the medial quadriceps tendon femoral ligament, a distinct anatomical structure to the medial patellofemoral ligament. These combine to form the medial patellofemoral complex. This technical note describes a technique
Khalid Al‐Hourani, Xinning Li
wiley   +1 more source

A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent/metastatic head and neck squamous-cell carcinomas. [PDF]

ESMO Open
William WN, Feng L, Kies MS, Ahmed S, Blumenschein GR, Glisson BS, Massarelli E, Johnson FM, Lu C, Le X, Kowalski LP, Kim ES.   +11 more
europepmc   +1 more source

Electroconvulsive Therapy for Catatonia in Autistic and Non‐Autistic Patients: An Observational Study on Course, Efficacy, Aggression, and Self‐Injury Outcomes

Autism Research, EarlyView.
ABSTRACT Catatonia occurs disproportionately in autistic individuals and may respond to electroconvulsive therapy (ECT), yet prior reports suggest greater treatment burden in this population. We compared longitudinal ECT utilization, safety, and clinical outcomes between autistic and non‐autistic patients with catatonia.
Joshua Ryan Smith, Maria Bonnee, Sarah Marler, Seri Lim, D. Catherine Fuchs, Rafael Tamargo, Isaac Baldwin, Christopher Maley, Ashley VanHaverbeck, Courtney Hamilton, Timothy Adegoke, Haozheng Xu, Jinyuan Liu, Zachary J. Williams, Jo Ellen Wilson, James Luccarelli   +15 more
wiley   +1 more source

Clinically actionable genomic alterations in breast cancer brain metastases. [PDF]

ESMO Open
Griguolo G, Collesei A, Lazzarini E, Bottosso M, Dieci MV, Fineberg S, Bauchet L, Landa G, Miglietta F, Jacob J, Rigau V, La Commare M, Trovò L, Fassan M, Jacot W, Dei Tos AP, Indraccolo S, Darlix A, Guarneri V.   +18 more
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Pharyngeal electrical stimulation for the treatment of dysphagia in Wallenberg syndrome: A FEES-based case analysis. [PDF]

eNeurologicalSci
Hinkelmann F, Kaspari M, Wojtecki L.
europepmc   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Can We Finally Identify the Psychological Effect of Body Size? A Century From Kretschmer to Mendelian Randomization. [PDF]

J Epidemiol
Narita ZC, Shinozaki T, Furukawa TA, Nishida A.   +3 more
europepmc   +1 more source